TABLE 3.

Any grade adverse events occurring in ≥2 patients and grade 3–4 adverse events

Adverse events	Cohort A Treatment‐naïve (N = 18)		Cohort B Relapsed/refractory (N = 9)		All (N = 27)
	Any grade	Grade 3–4	Any grade	Grade 3–4	Any grade	Grade 3–4
Any	18 (100)	7 (39)	9 (100)	5 (56)	27 (100)	12 (44)
Rash	11 (61)	0	1 (11)	0	12 (44)	0
Neutropenia	3 (17)	2 (11)	5 (56)	4 (44)	8 (30)	6 (22)
Nasopharyngitis	3 (17)	0	4 (44)	0	7 (26)	0
Leukopenia	2 (11)	0	4 (44)	3 (33)	6 (22)	3 (11)
Lymphopenia	2 (11)	2 (11)	3 (33)	3 (33)	5 (19)	5 (19)
Stomatitis	3 (17)	0	2 (22)	0	5 (19)	0
Constipation	3 (17)	0	1 (11)	0	4 (15)	0
Insomnia	3 (17)	0	1 (11)	0	4 (15)	0
Pneumonia	3 (17)	0	1 (11)	0	4 (15)	0
Hypertriglyceridemia	2 (11)	1 (6)	1 (11)	0	3 (11)	1 (4)
Diarrhea	3 (17)	0	0	0	3 (11)	0
Pruritus	3 (17)	0	0	0	3 (11)	0
Rash maculopapular	3 (17)	0	0	0	3 (11)	0
Thrombocytopenia	3 (17)	0	0	0	3 (11)	0
Nausea	2 (11)	0	1 (11)	0	3 (11)	0
Pyrexia	2 (11)	0	1 (11)	0	3 (11)	0
Purpura	1 (6)	0	2 (22)	0	3 (11)	0
Dry skin	2 (11)	0	0	0	2 (7)	0
Joint pain	2 (11)	0	0	0	2 (7)	0
Paronychia	2 (11)	0	0	0	2 (7)	0
Upper respiratory tract infection	2 (11)	0	0	0	2 (7)	0
Urinary tract infection	2 (11)	0	0	0	2 (7)	0
Atrial fibrillation	1 (6)	0	1 (11)	0	2 (7)	0
Cataract	1 (6)	0	1 (11)	0	2 (7)	0
Epistaxis	1 (6)	0	1 (11)	0	2 (7)	0
Hyperkalemia	1 (6)	0	1 (11)	0	2 (7)	0
Indigestion	1 (6)	0	1 (11)	0	2 (7)	0
Pharyngitis	1 (6)	0	1 (11)	0	2 (7)	0
Weight decreased	1 (6)	0	1 (11)	0	2 (7)	0
Bronchitis	0	0	2 (22)	0	2 (7)	0
Contusion	0	0	2 (22)	0	2 (7)	0
Fall	0	0	2 (22)	0	2 (7)	0
Anaphylactic reaction	1 (6)	1 (6)	0	0	1 (4)	1 (4)
Atypical mycobacterial infection	1 (6)	1 (6)	0	0	1 (4)	1 (4)
Erythema multiforme	1 (6)	1 (6)	0	0	1 (4)	1 (4)
Increased lipase	1 (6)	1 (6)	0	0	1 (4)	1 (4)
Rash erythematous	1 (6)	1 (6)	0	0	1 (4)	1 (4)
Rhegmatogenous retinal detachment	1 (6)	1 (6)	0	0	1 (4)	1 (4)
Type 2 diabetes	0	0	1 (11)	1 (11)	1 (4)	1 (4)

Adverse events occurring in ≥2 patients and those with grade 3–4 are listed. Number (%) of patients is shown.